Trial Profile

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients with Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irofulven (Primary) ; Spironolactone
Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Brain cancer; Brain metastases; Gastrointestinal stromal tumours; Glioblastoma; Glioma; Lung cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Thymic epithelial tumour; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Lantern Pharma

Most Recent Events

30 Mar 2026 According to Lantern Pharma media release, The Phase 1a trial which enrolled 63 patients.
03 Dec 2025 According to Lantern Pharma media release, Phase 1a dose-escalation study has been completed.
03 Dec 2025 Results published in the Lantern Pharma Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com